reports
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 ...
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated in the first half of 2026 SAN MATEO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathway...
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce B...
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced its participation in a drug development panel at Fierce Biotech Week taking place October 7-9, 2025 in Boston, MA. Panel Title:How Biotechs are Leveraging Artificial Intelligence (AI)/Machine Learning (ML) to Drive Efficiency and ROIPresenter: Marie O’Farrell, Ph...
- Jonathan Moreland
SNPS SYNOPSYS INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
NGL NGL ENERGY PARTNERS LP
MTDR MATADOR RESOURCES COMPANY
FRPT FRESHPET INC
BUSE FIRST BUSEY CORPORATION
ASA ASA
CELC CELCUITY
MBIN MERCHANTS BANCORP
AROC ARCHROCK INC.
CCEL CRYO-CELL INTERNATIONAL
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ALXO ALX ONCOLOGY HOLDINGS
DLHC DALEIGH HOLDINGS CORP
AMR ALPHA METALLURGICAL RESOURCES INC
OPEN OPENDOOR TECHNOLOGIES INC.
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
NEXT NEXT CAPITAL
RYAN RYAN SPECIALTY GROUP HLDGS INC
KMPH KEMPHARM INC
BUKS BUTLER NATIONAL CORP
OBLG OBLONG INC
VANI VIVANI MEDICAL INC
RH RESTORATION HARDWARE HOLDINGS INC
SMRT SMARTRENT INC
NBBK NB BANCORP INC.
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
CAMP CAMP4 THERAPEUTICS CORPORATION
SI SHOULDER INNOVATIONS INC
MSTR MICROSTRATEGY INCORPORATED
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate...
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, for development in acne SAN MATEO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pat...
- Jonathan Moreland
MTDR MATADOR RESOURCES COMPANY
ASA ASA
PBHC PATHFINDER BANCORP INC.
NEXT NEXTDECADE
CELC CELCUITY
FGBI FIRST GUARANTY BANCSHARES
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
OPEN OPENDOOR TECHNOLOGIES INC.
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
RYAN RYAN SPECIALTY GROUP HLDGS INC
KMPH KEMPHARM INC
NBBK NB BANCORP INC.
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
CAMP CAMP4 THERAPEUTICS CORPORATION
SI SHOULDER INNOVATIONS INC
- Jonathan Moreland
SBH SALLY BEAUTY HOLDINGS INC.
PRGO PERRIGO CO. PLC
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
GLP GLOBAL PARTNERS LP
FRPT FRESHPET INC
FLDM FLUIDIGM
FCN FTI CONSULTING INC.
CPRX CATALYST PHARMACEUTICALS
CE CELANESE CORPORATION
CDNA CAREDX INC
ASA ASA
AROW ARROW FINANCIAL CORP.
MDU MDU RESOURCES GROUP INC
ADC AGREE REALTY CORPORATION
CECE CECO ENVIRONMENTAL CORP.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BHB BAR HARBOR BANKSHARES
MFIN MEDALLION FINANCIAL CORP.
BSM BLACK STONE MINERALS LP
PLSE PULSE BIOSCIENCES
MLP MAUI LAND & PINEAPPLE CO. INC.
CELC CELCUITY
BRT BRT APARTMENTS
CCEL CRYO-CELL INTERNATIONAL
AEYE AUDIOEYE INC
DLHC DALEIGH HOLDINGS CORP
OPCH OPTION CARE HEALTH INC
SMMT SUMMIT THERAPEUTICS INC
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
NAUT NAUTILUS BIOTECHNOLOGY INC
ENOV ENOVIS CORPORATION
PFHC PROFRAC HLDG CORP
MLYS MINERALYS THERAPEUTICS INC
PROP PRAIRIE OPERATING CO.
DMA DESTRA MULTI ALTERNATIVE FUND
CAMP CAMP4 THERAPEUTICS CORPORATION
SFD SMITHFIELD FOODS INC.
AFCG AFC GAMMA
HYMC INC.
NIQ HYCROFT MINING HOLDING CORPORATION
NIQ GLOBAL INTELLIGENCE PLC
- Jonathan Moreland
FRPT FRESHPET INC
FLDM FLUIDIGM
FCN FTI CONSULTING INC.
ASA ASA
BHB BAR HARBOR BANKSHARES
MFIN MEDALLION FINANCIAL CORP.
BRT BRT APARTMENTS
SMMT SUMMIT THERAPEUTICS INC
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
ENOV ENOVIS CORPORATION
DMA DESTRA MULTI ALTERNATIVE FUND
CAMP CAMP4 THERAPEUTICS CORPORATION
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MAS...
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit SAN MATEO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company will give two oral presentations and participate in a drug development panel at the 9th Annual MASH Drug Development Summit taking place September 29-October 1, 2025 in Boston, MA. The two presentations will cover combination treatm...
Strawberry Fields REIT Announces Acquisition of $5.3 Million Skilled N...
Strawberry Fields REIT Announces Acquisition of $5.3 Million Skilled Nursing/Assisted Living Facility in Missouri SOUTH BEND, Ind., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) (the “Company”) today announced, it completed the acquisition of a facility comprised of 108 skilled nursing beds and 16 assisted living beds for $5.3 million located in Poplar Bluff, Missouri. The facility was added to an existing Master Lease with an affiliate of Reliant Care Group L.L.C. The acquisition will increase the Company's annual rents by $530 thousand dollars an...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
HTH HILLTOP HOLDINGS INC.
FLDM FLUIDIGM
COTY COTY INC. CLASS A
UPS UNITED PARCEL SERVICE INC. CLASS B
ASA ASA
MX MAGNACHIP SEMICONDUCTOR CORP.
ELTP ELITE PHARMACEUTICALS INC
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
MYO MYOMO
EBC EASTERN BANKSHARES INC
SUNS SUNRISE REALTY TRUST
GF THE NEW GERMANY FUND
AFCG INC.
SST AFC GAMMA
STSS INC.
SYSTEM1 INC
SHARPS TECHNOLOGY INC.
Sagimet Biosciences to Participate in Two Upcoming Investor Conference...
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Cantor Global Healthcare Conference in New York on September 3, 2025, with a fireside chat at 1:35 p.m. ET / 10:35 a.m. PT; andH.C. Wainwright 27th Annual Global Investment Conference in New York on September 9,...
- Jonathan Moreland
GLP GLOBAL PARTNERS LP
ASA ASA
TZOO TRAVELZOO
MLP MAUI LAND & PINEAPPLE CO. INC.
MBIN MERCHANTS BANCORP
WU THE WESTERN UNION COMPANY
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ASAN ASANA
ZIP ZIPRECRUITER
ENOV INC.
OBIO ENOVIS CORPORATION
SMRT ORCHESTRA BIOMED HOLDINGS INC
PROP SMARTRENT INC
BKKT PRAIRIE OPERATING CO.
MDRR BAKKT HOLDINGS INC.
MEDALIST DIVERSIFIED REIT INC.
- Jonathan Moreland
HTH HILLTOP HOLDINGS INC.
CE CELANESE CORPORATION
ASA ASA
ADC AGREE REALTY CORPORATION
HTLD HEARTLAND EXPRESS INC.
PLBC PLUMAS BANCORP
SMRT SMARTSPACE SOFTWARE
EOLS EVOLUS INC
GRNT GRANIT SKOPKE
MYO MYOMO
ATAI ATAI LIFE SCIENCES BV
PFHC PROFRAC HLDG CORP
MSDL MORGAN STANLEY DIRECT LENDING
DMA DESTRA MULTI ALTERNATIVE FUND
- Yun Zhong
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and ...
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 being developed for acne in the U.S. Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 SAN MATEO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- S...
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PEGA PEGASYSTEMS INC.
NVDA NVIDIA CORPORATION
CXW CORECIVIC INC.
INOD INNODATA
PTGX PROTAGONIST THERAPEUTICS
ARGX ARGENX ADS
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
U UNITY SOFTWARE
AI C3.AI
RBLX ROBLOX
APP APPLOVIN CORP
ATXS ASTRIA THERAPEUTICS INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
SGMT SAGIMET BIOSCIENCES INC
- Yun Zhong
Strawberry Fields REIT Announces Q3 2025 Cash Dividend of $0.16 per Co...
Strawberry Fields REIT Announces Q3 2025 Cash Dividend of $0.16 per Common Share SOUTH BEND, Ind., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) (the “Company”) today announced that its Board of Directors declared a cash dividend on its common stock in the amount of $0.16 per share (the “Dividend”). The Dividend will be payable in cash on September 30, 2025, to stockholders of record as of the close of business on September 16, 2025. Moishe Gubin, the Company’s Chairman & CEO, noted: “A stable dividend is a key component to our Company and I am exci...
Strawberry Fields REIT Announces Second Quarter 2025 Operating Results
Strawberry Fields REIT Announces Second Quarter 2025 Operating Results SOUTH BEND, Ind., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) (the “Company”) reported today its operating results for the quarter ended June 30, 2025. FINANCIAL HIGHLIGHTS 100% of contractual rents collected.On April 4, 2025, the Company completed the acquisition for a skilled nursing facility with 112 licensed beds near Houston, Texas. The acquisition was for $11.5 million. The Company funded the acquisition utilizing cash from the balance sheet. The facility was leased to ...
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annua...
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 2 p.m. EDT in Boston, MA. A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s we...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.